{"id":17467,"date":"2022-11-07T09:46:48","date_gmt":"2022-11-07T09:46:48","guid":{"rendered":"https:\/\/touchrespiratory.com\/?post_type=media_gallery&#038;p=17467"},"modified":"2022-12-14T10:28:42","modified_gmt":"2022-12-14T10:28:42","slug":"marc-simon-chest-2022-clinical-benefits-with-a-higher-dose-of-liq861-in-pulmonary-arterial-hypertension-analysis-of-the-lti-301-clinical-trial","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/pulmonary-hypertension\/conference-hub\/marc-simon-chest-2022-clinical-benefits-with-a-higher-dose-of-liq861-in-pulmonary-arterial-hypertension-analysis-of-the-lti-301-clinical-trial\/","title":{"rendered":"Marc Simon, CHEST 2022: Clinical benefits with a higher dose of LIQ861 in pulmonary arterial hypertension &#8211; analysis of the LTI-301 clinical trial"},"content":{"rendered":"<p>INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03399604\" target=\"_blank\" rel=\"noopener\">NCT03399604<\/a>). touchRESPIRATORY were delighted to talk with <strong>Dr. Marc Simon<\/strong> (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from his exploratory efficacy analysis of the study looking at clinical benefits with a higher dose of LIQ861.<\/p>\n<p>The abstract \u2018GREATER CLINICAL BENEFITS FROM HIGHER DOSES OF INHALED LIQ861 THAN LOWER DOSES: EXPLORATORY EFFICACY ANALYSES FROM THE LTI-301 CLINICAL TRIAL.\u2019 (Poster 2081) was presented at\u00a0<a href=\"https:\/\/www.chestnet.org\/Learning-and-Events\/Events\/CHEST-Annual-Meeting\" target=\"_blank\" rel=\"noopener\">CHEST 2022<\/a>, 16-19 October, 2022.<\/p>\n<p><strong>Questions<\/strong><\/p>\n<ol>\n<li>What were the aims, design and eligibility criteria of the LTI-301 clinical trial? (0:13)<\/li>\n<li>What have been the exploratory efficacy findings of the study? (2:36)<\/li>\n<li>What did trial participants think of this formulation? (3:46)<\/li>\n<\/ol>\n<p><b>Disclosures:<\/b> Marc Simon discloses consulting for ImpulseDynamics and serving on advisory boards for Acceleron, Aerovate, Janssen, and Liquidia.<\/p>\n<p><b>Support:<\/b>\u00a0Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/p>\n<p><b><i>Filmed in coverage of the CHEST meeting 2022.<\/i><\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from [&hellip;]<\/p>\n","protected":false},"featured_media":17465,"template":"","class_list":["post-17467","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-pulmonary-hypertension","video_categories-chest-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/17467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":6,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/17467\/revisions"}],"predecessor-version":[{"id":17596,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media_gallery\/17467\/revisions\/17596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media\/17465"}],"wp:attachment":[{"href":"https:\/\/touchrespiratory.com\/wp-json\/wp\/v2\/media?parent=17467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}